Overview

Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying the side effects of combination chemotherapy and to see how well it works in treating adult patients with newly diagnosed acute lymphoblastic leukemia.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
6-Mercaptopurine
Cortisol succinate
Cyclophosphamide
Cytarabine
Dexamethasone
Doxorubicin
Etoposide
Etoposide phosphate
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydrocortisone hemisuccinate
Imatinib Mesylate
Liposomal doxorubicin
Mercaptopurine
Methotrexate
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Pegaspargase
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Prednisone
Vincristine
Criteria
DISEASE CHARACTERISTICS:

- Diagnosis of acute lymphoblastic leukemia (ALL)

- No known mature B-cell ALL*, defined by the presence of surface immunoglobulin, L3
morphology, t(8;14)(q24;q32), t(8;22), or t(2;8)

- Patients with T-cell surface markers and t(8;14)(q24;q11) are eligible NOTE:
*Patients with mature B-cell ALL will be removed from the study as soon as that
diagnosis is made.

- No secondary ALL (i.e., ALL arising after another malignancy)

PATIENT CHARACTERISTICS:

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No known HIV positivity (HIV testing is not required)

- No comorbid medical condition that would, in the investigator's opinion, make
participation in this study and adherence to the study guidelines a compromise to the
study objectives

- No active psychiatric or mental illness that would make giving informed consent or
careful clinical follow-up unlikely

PRIOR CONCURRENT THERAPY:

- No prior anti-leukemic therapy except ≤ 1 week of steroids, emergent radiotherapy to
the mediastinum, hydroxyurea, or emergent leukapheresis

- Patients who have received steroids within the past 7 days are eligible but will
not receive steroid prophase therapy on study

- No concurrent chronic steroids or anti-metabolite therapy